{
    "organizations": [],
    "uuid": "8b5375c7c0000347f63c8847d38048a6938139f0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-rovi-sees-2018-operating-revenue-g/brief-rovi-sees-2018-operating-revenue-growth-at-mid-single-digit-rate-idUSFWN1QA095",
    "ord_in_thread": 0,
    "title": "BRIEF-Rovi Sees 2018 Operating Revenue Growth At Mid-Single-Digit Rate",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Laboratorios Farmaceuticos ROVI SA (ROVI) :\n* FOR 2018 SEES A MID-SINGLE-DIGIT GROWTH RATE FOR OPERATING REVENUE WITH A RANGE OF 20 MILLION EURO - 30 MILLION EURO SALES OF ENOXAPARIN BIOSIMILAR‍​\n* TO PROPOSE A DIVIDEND OF 0.1207 EUROS PER SHARE FOR FY 2017\n* FY EBITDA DOWN 22 PERCENT AT 30.5 MILLION EUROS VERSUS 39.3 MILLION EUROS YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-20T15:38:00.000+02:00",
    "crawled": "2018-02-21T21:15:40.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "laboratorios",
        "farmaceuticos",
        "rovi",
        "sa",
        "rovi",
        "see",
        "growth",
        "rate",
        "operating",
        "revenue",
        "range",
        "million",
        "euro",
        "million",
        "euro",
        "sale",
        "enoxaparin",
        "propose",
        "dividend",
        "euro",
        "per",
        "share",
        "fy",
        "fy",
        "ebitda",
        "percent",
        "million",
        "euro",
        "versus",
        "million",
        "euro",
        "year",
        "ago",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}